Opens in a new tab

Condolences Regarding the “2026 Kumamoto Earthquake”

Announcement

Tokyo, Japan:  We at Global Regulatory Partners sincerely extend our sympathies to everyone affected by the Kumamoto earthquake that occurred on July 28, 2026. 

We also express our heartfelt condolences to those who lost their lives due to this earthquake and offer our deepest sympathy to their families. 

At this time, there has been no confirmed impact on the supply of pharmaceuticals handled by Global Regulatory Partners GK. 

We sincerely hope for the swift recovery and reconstruction of the affected areas.

ABOUT GLOBAL REGULATORY PARTNERS
Global Regulatory Partners (GRP) is a leading provider of integrated regulatory affairs, compliance, and commercialization solutions for pharmaceutical, biotechnology, and medical device companies entering Japan. By serving as a Market Authorization Holder (MAH) in Japan, GRP simplifies market entry, accelerates regulatory approval timelines, and enables faster patient access to innovative healthcare products throughout the product lifecycle.
To learn more about Global Regulatory Partners and its services in Japan, visit globalregulatorypartners.co.jp.

Related News

  • Baqsimi® Nasal Powder Featured in the September 2026 Issue of Nikkei DI

    Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi® Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.
    View More

  • GRP JAPAN JOINS THE JAPAN RADIOPHARMACEUTICALS ASSOCIATION

    Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.
    View More

  • Global Regulatory Partners to Exhibit at BioJapan  2026

    Global Regulatory Partners (GRP) is pleased to announce its participation in BioJapan  2026, where GRP will exhibit at Booth C-41 and participate in the event's international Partnering program. BioJapan  2026 is observing its 40th anniversary as the world’s longest running biotechnology event.  It is held together with concurrent events,Regenerative Medicine JAPAN, and healthTECH JAPAN, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.
    View More

  • Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan

    Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.
    View More